77779-36-3

Usage

InChI:InChI=1/C16H10ClN3O/c17-10-5-7-11(8-6-10)20-16(21)13-9-18-14-4-2-1-3-12(14)15(13)19-20/h1-9,19H

Upstream product

• 13720-94-0 ethyl 4-chloroquinoline-3-carboxylate 
• 1073-69-4 N-4-chlorophenylhydrazine 
• 26892-90-0 ethyl 4-hydroxy-3-quinolinecarboxylate 
• 62-53-3 aniline 
• 7440-06-4 platinum 

Downstream Products

• 77779-40-9 1-methyl-2-(p-chlorophenyl)-pyrazolo[4,3-c]quinolin-3-one 
• 77779-41-0 5-methyl-2-(p-chlorophenyl)-pyrazolo[4,3-c]quinolin-3-one 
• 77792-53-1 5-(3-dimethylaminopropyl)-2-(p-chlorophenyl)-pyrazolo-[4-3-c]quinolin-3-one 
• 1118099-79-8 3-[(2-chlorobenzyl)oxy]-2-(4-chlorophenyl)-2H-pyrazolo[4,3-c]quinoline 
• 149743-54-4 CGS-9896 

Relevant academic research and scientific papers

High affinity central benzodiazepine receptor ligands. Part 2: Quantitative structure-activity relationships and comparative molecular field analysis of pyrazolo[4,3-c]quinolin-3-ones

A large series of 2-aryl(heteroaryl)-2,5-dihydropyrazolo[4,3-c]quinolin-3(3H)-ones (PQ, 106 compounds), carrying appropriate substituents at the quinoline and N2-phenyl rings, were designed, prepared and tested as central benzodiazepine recepto

Structure-activity relationship studies at the benzodiazepine receptor (BZR): A comparison of the substituent effects of pyrazoloquinolinone analogs

The synthesis of a series of 2-phenylpyrazolo[4,3-c]quinolin-3-one derivatives and their in vitro biological evaluation as ligands for the benzodiazepine receptor are described. The in vitro activities, as determined by an analysis of GABA shift ratios, a

Pyrazoloquinolines

2-Aryl-pyrazolo[4-3-c]quinolin-3-ones, e.g. those of the formula STR1 and pharmaceutically acceptable acyl derivatives or salts thereof, are psychoactive agents useful in the treatment of anxiety or depression.